Combined, our data suggest that TSLP-activation of RAS in the absence of RAS mutations drives B-ALL cell growth, and represents an independent drug target, in addition to the PI3K/mTOR and JAK/STAT pathway targets. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.